N-[(1-芳基-3-苯基-吡唑-4-基)次甲基]-2-羟基苯甲酰肼类衍生物的合成、表征及抑菌活性

高等学校化学学报 ›› 2010, Vol. 31 ›› Issue (8): 1590.

N-[(1-芳基-3-苯基-吡唑-4-基)次甲基]-2-羟基苯甲酰肼类衍生物的合成、表征及抑菌活性

邹敏¹, 卢俊瑞¹, 辛春伟¹, 卢博为², 朱姗姗¹, 刘倩¹, 李佳潼¹, 邱建波¹, 鲍秀荣¹

1. 天津理工大学化学化工学院, 天津 300384;
2. 南开大学化学学院, 天津 300071

收稿日期:2009-10-30 出版日期:2010-08-10 发布日期:2010-08-10
通讯作者: 卢俊瑞, 男, 博士, 教授, 博士生导师, 主要从事新型精细化学品研究. E-mail: lujunrui@tjut.edu.cn
基金资助:
国家自然科学基金(批准号: 20776114, 20976135)和天津市高等学校科技发展基金(批准号: 2006ZD33)资助.

Synthesis, Characterization and Antibacterial Activities of N-[(1-Aryl-3-phenyl-pyrazol-4-yl)methylene]-2-hydroxybenzohydrazide Derivatives

ZOU Min¹, LU Jun-Rui^1*, XIN Chun-Wei¹, LU Bo-Wei², ZHU Shan-Shan¹, LIU Qian¹, LI Jia-Tong¹, QIU Jian-Bo¹, BAO Xiu-Rong¹

1. School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin 300384, China;
2. College of Chemistry, Nankai University, Tianjin 300071, China)

Received:2009-10-30 Online:2010-08-10 Published:2010-08-10
Contact: LU Jun-Rui. E-mail: lujunrui@tjut.edu.cn
Supported by:
国家自然科学基金(批准号: 20776114, 20976135)和天津市高等学校科技发展基金(批准号: 2006ZD33)资助.

摘要/Abstract

摘要： 依据生物活性叠加原理, 以邻羟苯基和苯基吡唑为分子核心, 构建了6种未见报道的N-[(1-芳基-3-苯基-吡唑-4-基)次甲基]-2-羟基苯甲酰肼衍生物. 以芳胺为原料, 经重氮化、还原、与苯乙酮缩合及Vilsmeier-Haack反应制得1-芳基-3-苯基-4-甲酰基吡唑, 再与水杨酰肼反应制得目标化合物, 其结构经IR, ¹H NMR和元素分析等验证. 探讨了制备中间体(3a~3f)的反应机理, 结果表明, 1位芳环上取代基对关环反应有显著影响, 供电基有利于关环反应的进行, 吸电基则恰恰相反. 抗菌活性测试表明, 质量分数为0.01%的化合物对大肠杆菌和白色念珠菌的抑菌率高达100%, 有极强的抑菌活性, 对金黄色葡萄球菌的抑菌率达70%以上, 有一定的抑菌活性, 是一类极具潜力的抗真菌和抗革兰氏阴性菌的化合物. 构效分析结果表明, 1位芳基中引入Cl和Br等卤原子, 能显著增强化合物的抑菌活性, 而引入NO2和CH3基团, 则会降低其抑菌活性.

关键词: N-[(1-芳基-3-苯基-吡唑-4-基)次甲基]-2-羟基苯甲酰肼, 衍生物, 抑菌活性

Abstract: A series of novel N-[(1-aryl-3-phenyl-pyrazol-4-yl)methylene]-2-hydroxybenzohydrazide derivatives were designed and synthesized by combining o-hydroxyl phenyl and phenyl pyrazole with hydrazone bond, according to the superposition principle of biological activities. Six compounds are all novel. Substituted aniline was diazotized and subsequently reduced to give substituted phenylhydrazine, acetophenone arylhydrazone were obtained by the condensation of acetophenone with substituted phenylhydrazine. 1-Aryl-3-phenyl-4-formylpyrazoles were obtained with N,N-dimethylformamide and phosphorus oxychloride, which was reacted with salicylic hydrazide to get the title compounds. The structures of all title compounds were confirmed by ¹H NMR, IR and elemental analysis. The reaction mechanism of acquiring 3a—3f show that catalytic reaction activity is enhanced by electron-donating groups of the first phenyl ring, but reduced by electron-withdrawing groups of the first phenyl rings. The result of preliminary bioassay show that the inhibitory rate against Monilia albican and Escherichia coli of the title compounds can be high to 100% at 0.01% mass fraction, inhibitory rate against Staphlococcus aureus is over 70%. They will be a series of potential antibacterial compounds against fungi and gram-negative bacteria. The analysis of structure-activity relationship show that the antibacterial activities of title compounds are enhanced by the halogen groups of the phenyl ring, but reduced by electron-donating and electron-withdrawing groups of the phenyl ring, such as NO₂ and CH₃.

Key words: N-[(1-Aryl-3-phenyl-pyrazol-4-yl)methylene]-2-hydroxybenzohydrazide, Derivative, Antibacterial-activity

TrendMD:

邹敏, 卢俊瑞, 辛春伟, 卢博为, 朱姗姗, 刘倩, 李佳潼, 邱建波, 鲍秀荣. N-[(1-芳基-3-苯基-吡唑-4-基)次甲基]-2-羟基苯甲酰肼类衍生物的合成、表征及抑菌活性. 高等学校化学学报, 2010, 31(8): 1590.

ZOU Min, LU Jun-Rui*, XIN Chun-Wei, LU Bo-Wei, ZHU Shan-Shan, LIU Qian, .... Synthesis, Characterization and Antibacterial Activities of N-[(1-Aryl-3-phenyl-pyrazol-4-yl)methylene]-2-hydroxybenzohydrazide Derivatives. Chem. J. Chinese Universities, 2010, 31(8): 1590.

参考文献

[1]McMurray L. M., Oethinger M., Levy S. B.. Nature[J], 1998, 394(6): 531—532 [2]Heath R. J., Yu Y.T., Shapiro M. A.. Journal of Biological Chemistry[J], 1999, 273(46): 30316—30320 [3]Sivaraman S.. J. Med. Chem.[J], 2004, 47: 509—5l8 [4]LU Jun-Rui(卢俊瑞), MA Xia-Miao(马霞苗), LIU Mei(刘梅), YIN Ning(尹宁), CHEN Li-Ran(陈立然), BAO Xiu-Rong(鲍秀荣). Chem. J. Chinese Universities(高等学校化学学报)[J], 2007, 28(11): 2081—2085 [5]Abdel-Hafez E. S., Abuo-Rahma G. E. D., Abdel-Aziz M., Radwan M. F., Farag H. H.. Bioorg. Med. Chem.[J], 2009, 17: 3829—3837 [6]Tanitame A., Oyamada Y., OfuJi K., Fujimoto M., Iwai N, Hiyama Y., Suzuki K., Ito H., Terauchi H., Kawasaki M., Nagai K., Wachi M., Yamagishi J.. J. Med. Chem.[J], 2004, 47(14): 3693—3696 [7]Genin M. J., Biles C., Keiser B. J., Swaney S. M., Tarpley W. G., Yagi Y., Romero D. L.. J. Med. Chem.[J], 2000, 43(5): 1034—1040 [8]Xia Y., Fan C. D., Zhao B. X., Zhao J., Shin D. S., Miao J. Y.. Eur. J. Med. Chem.[J], 2008, 43(11): 2347—2353 [9]Xia Y., Dong Z. W., Zhao B. X., Ge X., Meng N., Shin D. S, Miao J. Y.. Bioorg. Med. Chem.[J], 2007, 15(22): 6893—6899 [10]Dalla V. L., Marini A. M., Salerno S., La Motta C.,Condello M., Arancia G., Agostinelli E., Toninello A.. Bioorg. Med. Chem.[J], 2009, 17(1): 326—336 [11]Akbas E., Berber I., Sener A.. Il Farmaco[J], 2005, 60(1): 23—26 [12]Prakash O., Kumar R., Parkash V.. Eur. J. Med. Chem.[J], 2008, 43: 435—440 [13]Helmerhost E. J., Breeuwer P., Hof W. V., Walgreen-Weterings E., Oomen L. C. J. M., Veerman E. C. I., Amerongen A. V. N., Abee T.. J. Biol. Chem.[J], 1999, 274(11): 7286—7291 [14]Ji H. T., Zhang W. N., Zhou Y. J., Zhang M., Zhu J., Song Y. L., Lu J., Zhu J.. J. Med. Chem.[J], 2000, 43(13) : 2493—2505 [15]SHENG Chun-Quan(盛春泉), JI Hai-Tao(季海涛), ZHANG Wan-Nian(张万年). Chinese Journal of New Drugs(中国新药杂志)[J], 2002, 11(4): 278—281 [16]PAN Fu-You(潘富友), YANG Jian-Guo(杨健国), LIANG Hua-Ding(梁华定), GE Chang-Hua(葛昌华). Chinese Journal Applied Chemistry(应用化学)[J], 2001, 18(12): 1001—1003